Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 19Active not recruiting 8Completed 7Unknown 6Withdrawn 4Terminated 3Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × OTHER × lutetium Lu 177 dotatate × Clear all
NCT05987176 2026-01-14

NELMAS

Imperial College London

Phase 2 Terminated
1 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02489604 2025-01-13

LUNET

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
70 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡